Treatment of precocious puberty in McCune-Albright syndrome

Jakub Mieszczak, Erica A. Eugster

Research output: Contribution to journalReview articlepeer-review

28 Scopus citations


McCune-Albright syndrome (MAS) is typically defined as a triad of precocious puberty (PP), café au lait spots and fibrous dysplasia of bone. PP is the most common endocrinological manifestation of this rare disease and is much more common in girls than in boys. The treatment options for PP associated with MAS have evolved over the last twenty plus years. Therapy in girls typically includes the use of an anti-estrogen, while treatment options in boys include an antiandrogen in combination with an aromatase inhibitor (AI). This article will briefly review the older therapies and explain why they have largely been supplanted by newer approaches. We will discuss current pharmacotherapy options for the treatment of PP in MAS and finally describe potential novel therapies that will hopefully enable optimal care for affected patients.

Original languageEnglish (US)
Pages (from-to)419-422
Number of pages4
JournalPediatric Endocrinology Reviews
Issue numberSUPPL. 4
StatePublished - Aug 2007


  • McCune-Albright syndrome
  • Precocious puberty
  • Treatment

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Endocrinology, Diabetes and Metabolism
  • Internal Medicine

Fingerprint Dive into the research topics of 'Treatment of precocious puberty in McCune-Albright syndrome'. Together they form a unique fingerprint.

Cite this